TRAF2-Binding Peptide for CD40 Inhibition

Solution Overview

Problem

Current methods for treating CD40-mediated diseases, such as inflammatory diseases, are hindered by the risk of platelet aggregation and thrombosis caused by blocking the CD40-CD154 pathway, and may impair host resistance to infections due to indiscriminate inhibition of the CD40 pathway.

Innovation Solution

Administering a therapeutically effective amount of an agent that inhibits the binding of TNF receptor-associated factor 2 (TRAF2) to the cytoplasmic portion of CD40, without affecting the binding of CD40 ligand (CD40L), to reduce pro-inflammatory responses like VCAM-1 upregulation, chemokine production, and tissue factor production, while avoiding platelet aggregation and maintaining cell-mediated immune response.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If anti-CD154 monoclonal antibodies are administered to block the CD40-CD154 pathway, then CD40-mediated inflammatory diseases are controlled, but platelet aggregation and thrombosis occur

Engineering Contradiction:

Improvecontrol of CD40-mediated diseasesVSAvoidplatelet aggregation and thrombosis

Core Design Contradiction:

ReliabilityVSObject-affected harmful factors

Solution Approach 1:

The invention segments the CD40 signaling pathway by targeting a specific downstream component (TRAF2 or its binding interaction with CD40) rather than blocking the entire CD40-CD154 pathway. This selective inhibition allows control of inflammatory responses while preserving other critical functions of the pathway, including platelet function and host resistance to infections.

Inventive Principle:

Principle #1Segmentation

Solution Approach 2:

The invention applies local quality by directing the blocking agent specifically to inhibit TRAF2 binding to the cytoplasmic portion of CD40, rather than indiscriminately blocking the entire CD40 pathway. This localized inhibition at a specific molecular interaction site achieves disease control while minimizing off-target effects on platelets and immune resistance.

Inventive Principle:

Principle #3Local quality

2Reliability

If the CD40 pathway is indiscriminately inhibited, then inflammatory responses are reduced, but host resistance to infections is impaired

Engineering Contradiction:

Improvereduction of inflammatory responsesVSAvoidsusceptibility to opportunistic infections

Core Design Contradiction:

ReliabilityVSObject-affected harmful factors

Solution Approach 1:

The invention segments the CD40 signaling pathway by targeting a specific downstream component (TRAF2 or its binding interaction with CD40) rather than blocking the entire CD40-CD154 pathway. This selective inhibition allows control of inflammatory responses while preserving other critical functions of the pathway, including platelet function and host resistance to infections.

Inventive Principle:

Principle #1Segmentation

Solution Approach 2:

The invention applies local quality by directing the blocking agent specifically to inhibit TRAF2 binding to the cytoplasmic portion of CD40, rather than indiscriminately blocking the entire CD40 pathway. This localized inhibition at a specific molecular interaction site achieves disease control while minimizing off-target effects on platelets and immune resistance.

Inventive Principle:

Principle #3Local quality

3Reliability

If CD40 signaling is blocked to treat inflammatory diseases, then pro-inflammatory responses are inhibited, but the cell-mediated immune response is impaired

Engineering Contradiction:

Improveinhibition of pro-inflammatory responsesVSAvoidimpairment of cell-mediated immune response

Core Design Contradiction:

ReliabilityVSObject-affected harmful factors

Solution Approach 1:

The invention segments the CD40 signaling pathway by targeting a specific downstream component (TRAF2 or its binding interaction with CD40) rather than blocking the entire CD40-CD154 pathway. This selective inhibition allows control of inflammatory responses while preserving other critical functions of the pathway, including platelet function and host resistance to infections.

Inventive Principle:

Principle #1Segmentation

Solution Approach 2:

The invention applies local quality by directing the blocking agent specifically to inhibit TRAF2 binding to the cytoplasmic portion of CD40, rather than indiscriminately blocking the entire CD40 pathway. This localized inhibition at a specific molecular interaction site achieves disease control while minimizing off-target effects on platelets and immune resistance.

Inventive Principle:

Principle #3Local quality

Data Source

PatentUS10669345B2Method for treating CD40-mediated diseases

Publication Date: 2020.06.02 CASE WESTERN RESERVE UNIV

AI summary

A cell-permeable polypeptide includes a membrane transduction domain and a polypeptide comprising an amino acid sequence substantially homologous to the amino acid sequence of the TRAF2,3 binding domain, the cell permeable peptide inhibiting binding of TRAF2 to the TRAF2,3 binding domain of CD40 to decrease or inhibit a CD-40 activity or signal transduction pathway associated with a CD40-mediated disease in cells of a subject.